Abstract: A probe can be situated within a tissue to perfuse one or more materials, collect material in response, and pass the collected material to a microdialysis probe situated external to the tissue based on fluid flow by electroosmosis. Perfusion and collection can be via orifices that are offset laterally and along a tissue depth. Variation of perfusion by varying materials perfused or rate of perfusion can be used to determine perfusion rates or other time-dependencies., concentrations of chemical species and rates of reactions of chemical species in the tissue.

Abstract: Ultrasound systems and methods of use are provided for rapidly heating a target area of a subject. The ultrasound system can include at least one imaging transducer array for imaging the target area, and at least two spaced-apart heating transducer arrays for heating the target area. The heating transducer arrays can be separated by the imaging transducer array on an ultrasound probe.

Abstract: A device for performing vector operations is provided. The device includes a photonic crossbar array. The photonic crossbar array includes a plurality of unit cells. One or more of the plurality of unit cells includes a beam splitter, a first photodetector, and a second photodetector. The one or more unit cells are configured to output, as a unit cell output, a third output of the optical signal and a fourth output of the optical signal. The device includes a controller configured to encode a first vector in time-varying amplitudes or time-varying phases of a first electric field, encode a second vector in time-varying amplitudes or time-varying phases of a second electric field, and determine a result of multiplication of the first vector and the second vector based on the unit cell output from the one or more of the plurality of unit cells.

Abstract: A method of predicting the risk of experiencing symptoms related to abnormal blood pressure and/or heart rate that includes obtaining subject heart rate variability data representing a number of HRV parameters, wherein the subject HRV data is generated based on heartbeat data obtained from an individual wearing a heart parameter sensor, providing the subject HRV data as an input to an artificial intelligence system, wherein the artificial intelligence system has been previously trained using training and test HRV data representing the number of HRV parameters obtained from a plurality of test subjects, and analyzing temporal data changes in or indicated by the subject HRV data in the artificial intelligence system to determine whether the individual is at risk of experiencing symptoms related to abnormal blood pressure and/or heart rate placing them at risk of a fall.

Abstract: A method of non-invasively assessing mitochondrial function in live tissue of a subject includes providing periodic hypoxia challenges to the subject during a cyclic oxygenation period, acquiring 4D BOLD fMRI data from the live tissue of the subject during the cyclic oxygenation period, and analyzing the acquired 4D BOLD fMRI data to determine a measure of mitochondrial function for each of a number of regions of the live tissue. Also, a system for non-invasively assessing mitochondrial function includes an fMRI system including a magnet, an RF system and a controller, wherein the controller is structured and configured to acquire 4D BOLD fMRI data from the live tissue of the subject during a cyclic oxygenation period wherein periodic hypoxia challenges are experienced by the subject, and analyze the acquired 4D BOLD fMRI data to determine a measure of mitochondrial function for each of a number of regions of the live tissue.

Abstract: A compound, or a pharmaceutically acceptable salt thereof, of formula I: wherein R1, R8, R9, R31, R32, R33, and R34 are each independently H, C1-C6 alkyl, or substituted C1-C6 alkyl; and R2, R4, R5, R6, and R7 are each independently H, F, Cl, Br, —OR1—NR8R9, C1-C6 alkyl, or substituted C1-C6 alkyl.

Abstract: The present invention includes methods, systems, uses, and means for the delivery of one or more anti-fibrotic agents into the pericardial space for the treatment and prevention of heart failure (HF).

Abstract: The present invention provides a method of targeted molecular imaging and/or targeted drug delivery, wherein two components or probes each interacts with one or more biomarkers on a cell and separately interact with each other to form a stable bond, such as a stable covalent bond. In certain non-limiting embodiments, at least one of the probes is photo-triggered to allow for bonding with at least one second probe. In certain non-limiting embodiments, the cell is a tumor or cancer cell. The present invention also relates to compounds, probes, and kits for use in targeted molecular imaging and/or targeted drug delivery.

Abstract: A method of generating a plurality of spatially co-registered data elements, each spatially co-registered data element being associated with and generated from a pair of co-registered tissue sections obtained from adjacent positions of a core taken from a tissue sample and including an image data section and a genomic data section. The method includes, for each pair of co-registered tissue sections: (i) obtaining and storing as part of a data element a plurality of multi to hyperplexed images from the imaging data section of the co-registered tissue section, (ii) generating and storing as part of the data element image data from the plurality of multi to hyperplexed images, and (iii) generating and storing as part of the data element genomic data from the genomic data section of the associated co-registered tissue section.

Abstract: A non-naturally occurring zinc finger protein, wherein the zinc finger protein specifically binds to the promoter region of the Myd88 gene, is provided, as well as related polynucleotides, vectors, cells, and pharmaceutical compositions. In some aspects, the zinc finger protein comprises one or more repressors. Pharmaceutical compositions comprising a pharmaceutically acceptable carrier and: (A) one or more RNA interference (RNAi) agents targeting the Myd88 gene, or related polynucleotides, vectors, or cells: (B) a target antigen or a polynucleotide encoding the target antigen; and (C) a gene therapy are also provided. Methods for ameliorating inflammation and/or immune response in a subject using the RNAi agents, zinc finger protein, polynucleotides, vectors, cells, and pharmaceutical compositions also are provided.

Abstract: The present disclosure provides methods for expanding tumor-infiltrating lymphocytes (TILs), such as tumor-infiltrating T cells, utilizing an agonist of PGC1? in vivo, ex vivo, or both. Exhausted T cells present in the TIL population fail to effectively proliferate, produce cytokines, or kill target cells. The present disclosure provides methods to correct these defects through the use of pharmacologic agents to reprogram the metabolism of the exhausted intratumoral T cells. Exemplary agonists of PGC1? include proliferator-activated receptor (PPAR)-gamma agonists (e.g., a thiazolidinedione (TZD), aleglitazar, farglitazar, muraglitazar, or tesaglitazar), AMPK activators (e.g., 5-aminoimidazole-4-carboxamide ribonucleotide, AICAR), and sirtuin activators (e.g., resveratrol, SRT1720, SRT2104, SRT2183, SRT1460). Also provided are kits can compositions that can be used with such methods.

Abstract: The present disclosure provides compositions, including modified peripheral blood mononuclear cells (PBMCs) with reduced expression of Slc16a11 and/or reduced activity of MCT11. Also provided are siRNAs and gRNAs targeting Slc16a11. Methods of using the disclosed compositions in the treatment of cancer are also provided.

Abstract: Methods of treating a disease, disorder or syndrome associated with a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (such as COVID-19) in a subject by administering one or more C-X-C chemokine receptor 3 (CXCR3) antagonist peptides are described. Diagnostic methods for enhancing replication of SARS-CoV-2 in cultured cells and/or detecting the presence of SARS-CoV-2 in cultured cells by contacting the cells with a CXCR3 agonist peptide are also described.

Abstract: Disclosed herein are endotracheal tubes that have external baffles near the distal end of the tube to reduce unwanted migration of the tube relative to the trachea and to help prevent materials from passing between the outside of the tube and the tracheal walls. The baffles can be made of soft flexible material that conforms to and seals against the trachea. The baffles can be angled proximally or distally, or both. The baffles can be tapered in thickness and can vary in radial length. Some embodiments can include a supraglottic umbrella. Some embodiments can include an axially expandable portion along the tube. Some embodiments can include a loading tube that helps set the deflection orientation of the baffles within the trachea.

Abstract: The invention includes an ex-situ biosensors that impedimetrically detect one or more target biomarkers of brain injury or disease in a bodily fluid sample derived from a patient. The biosensors include a multi-array of vertically aligned platinum wires having immobilized thereon antibody and/or aptamer that specifically and selectively bind to the one or more target biomarkers. An electrochemical impedance signal is generated, and a change in electrochemical impedance is indicative of the presence of the one or more target biomarker(s) in the bodily fluid sample. The biosensors are point-of-care, on-demand devices useful in a medical and domestic environment.

Abstract: A background correction method for a fluorescence microscopy system includes receiving a raw image stack, determining a number of temporal minimum intensity values for each pixel location from the raw image stack, and calculating an expected background value for each pixel location based on the number of temporal minimum intensity values for the pixel location. Also, an emitter localization method includes receiving a raw image stack, determining a rough position of each of a plurality of emitters within the raw image stack by employing a linear deconvolution process, and determining a precise position of each of the plurality of emitters by employing the rough position of the emitter and gradient fitting.

Abstract: The present disclosure relates to the methods of preventing and/or treating cancer including administering IL33 and anti-AREG antibodies or fragments thereof to a subject in need thereof. The present disclosure further provides compositions and kits for performing such methods.

Abstract: The present invention provides a multivalent compound for targeted molecular imaging and/or targeted drug delivery, wherein two components or targeting molecules each interacts with one or more biomarkers on a cell. The present invention further provides a multifunctional chelator to combine the targeting molecules. The present invention also provides an in vitro high-throughput screening assay to determine the length of the spacer molecules. The present invention also relates to compounds/probes, kits and methods for use in targeted molecular imaging and/or targeted drug delivery.

Abstract: Disclosed are pharmaceutical compositions comprising a combination of five or more phages and a pharmaceutically acceptable carrier, as well as methods of treating, reducing, or preventing a disease caused by Mycobacterium tuberculosis in a mammal, methods of treating an antibiotic resistant infection in a mammal, and methods of treating, reducing, or preventing activation of a latent disease caused by M. tuberculosis.

Abstract: A near-field probe (and associated method) compatible with near-infrared electromagnetic radiation and high temperature applications above 300°° C. (or 500° C. in some applications) includes an optical waveguide and a photonic thermal emitting structure comprising a near-field thermally emissive material coupled to or part of the optical waveguide. The photonic thermal emitting structure is structured and configured to emit near-field energy responsive to at least one environmental parameter of interest, and the near-field probe is structured and configured to enable extraction of the near-field energy to a far-field by coupling the near-field energy into one or more guided modes of the optical waveguide.